十氢异喹啉-6-醇 | 725228-44-4

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 十氢异喹啉-6-醇
• 英文名称: Decahydroisoquinolin-6-ol
• 英文别名: 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinolin-6-ol
• CAS: 725228-44-4
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: OIDWQGDFFZCQRK-UHFFFAOYSA-N

物化性质

• 沸点：
  264.5±40.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Octahydroisoquinoline compounds as opioid receptor modulators
  申请人：Carroll Ivy Frank

  公开号：US20070027182A1

  公开（公告）日：2007-02-01

  Compounds which bind to opioid receptors are provided. In a preferred embodiment of the invention, the compounds are opioid receptor antagonists. The present invention also provides methods of treating conditions which are mediated by an opioid receptor.

  提供结合到阿片受体的化合物。在发明的首选实施例中，这些化合物是阿片受体拮抗剂。本发明还提供了治疗由阿片受体介导的疾病的方法。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas Operations, Inc.

  公开号：EP3660004A1

  公开（公告）日：2020-06-03

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，它们可用于降解和（抑制）雄激素受体。特别是，本公开涉及的化合物一端含有与 E3 泛素连接酶结合的脑龙配体，另一端含有与雄激素受体结合的分子，这样雄激素受体就被置于泛素连接酶附近，从而实现对雄激素受体的降解（和抑制）。本公开的化合物具有广泛的药理活性，与雄激素受体的降解/抑制作用相一致。
• Compounds and methods for the targeted degradation of androgen receptor
  申请人：Arvinas Operations, Inc.

  公开号：US11236051B2

  公开（公告）日：2022-02-01

  The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，它们可用于降解（和抑制）雄激素受体。特别是，本公开涉及的化合物一端含有与 E3 泛素连接酶结合的脑龙配体，另一端含有与雄激素受体结合的分子，这样雄激素受体就被置于泛素连接酶附近，从而降解（和抑制）雄激素受体。本公开的化合物具有广泛的药理活性，与雄激素受体的降解/抑制作用相一致。
• OCTAHYDROISOQUINOLINE COMPOUNDS AS OPIOID RECEPTOR MODULATORS
  申请人：RESEARCH TRIANGLE INSTITUTE

  公开号：EP1906962A2

  公开（公告）日：2008-04-09
• US7476679B2
  申请人：——

  公开号：US7476679B2

  公开（公告）日：2009-01-13